Education
About Us
Working with TipRanks
Follow Us
Serina Therapeutics (SER)
:SER
SER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $14.57
Previous CloseN/A
Volume4.86K
Average Volume (3M)8.82K
Market Cap
$47.18M
Enterprise Value$80.15M
Total Cash (Recent Filing)$345.00K
Total Debt (Recent Filing)$4.37M
Price to Earnings (P/E)―
Beta-0.97
Next Earnings
May 20, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.94
Shares Outstanding9,932,215
10 Day Avg. Volume7,141
30 Day Avg. Volume8,821
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)338.74
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.76K
Enterprise Value/Ebitda-13.56
Forecast
1Y Price Target
$11.00Price Target Upside131.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Serina Therapeutics News
PremiumCompany Announcements
Serina Therapeutics Unveils Breakthrough in POZ-Lipid Technology
PremiumCompany Announcements
Serina Therapeutics Appoints Dr. Venkatesan to Board
PremiumCompany Announcements
Serina Therapeutics Secures $5 Million for SER-252 Trials
PremiumCompany Announcements
Serina Therapeutics Strengthens Board with New Appointment---
Bulls Say, Bears Say
Bulls Say
Market PotentialPOZ-Apomorphine targets substantial Advanced Parkinson's Disease market with potential for key clinical/commercial advantages.
Technology And InnovationSerina's core technology is based on the polymer poly(2-oxazoline) (POZ), which facilitates improved delivery of drugs administered subcutaneously.
Bears Say
Financial NeedsSerina will require additional capital to support development, with current cash expected to last through 2Q25.
---
Ownership Overview
71.15% Insiders
0.94% Mutual Funds
1.92% Other Institutional Investors
25.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $3.81 and its highest was $14.57 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $47.18M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is May 20, 2025 which is in 52 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Mar 24, 2025. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of $0.42 by -$1.55.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.62.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 9,932,215 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -$1.13 in its last earnings report, missing expectations of $0.42. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in SER
---
Serina Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (131.58% Upside)
$11.00 (131.58% Upside)
Insider Transactions
Bought Shares
Worth $17.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.05%
12-Months-Change
Fundamentals
Return on Equity
45.59%
Trailing 12-Months
Asset Growth
-39.11%
Trailing 12-Months
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
---
SER Stock 12 Month Forecast
Average Price Target
$11.00
▲(131.58% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Repligen
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering SER
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+1.40%
reiterated a buy rating 4 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +1.40% per trade.
---